Filter
246
Filtered Results: 246
Text search:
ivermectin
Featured
Recommendations
32
New Publications
60
Language
Document type
No document type
89
Guidelines
71
Studies & Reports
44
Strategic & Response Plan
17
Fact sheets
9
Manuals
7
Training Material
4
Brochures
2
Infographics
2
Situation Updates
1
Countries / Regions
Global
18
Brazil
11
Latin America and the Carribbean
9
Ethiopia
9
Uganda
8
Liberia
8
Sierra Leone
7
Germany
6
Congo, Democratic Republic of
6
Senegal
5
Burkina Faso
5
West and Central Africa
5
Benin
4
Mozambique
4
Middle East and North Africa
4
South Africa
4
India
4
Kenya
3
Togo
3
Nigeria
3
Africa
3
Paraguay
3
East and Southern Africa
3
Rwanda
2
Bolivia
2
Angola
2
El Salvador
1
Ghana
1
Chile
1
Cameroon
1
Niger
1
Burundi
1
Peru
1
Philippines
1
Guinea
1
Haiti
1
Guinea-Bissau
1
Tanzania
1
Côte d’Ivoire / Ivory Coast
1
Argentina
1
Russia
1
Yemen
1
Central African Republic
1
Mali
1
Chad
1
Zambia
1
South Sudan
1
Ecuador
1
Solomon Islands
1
Authors & Publishers
Publication Years
Category
COVID-19
34
Guidelines
30
Drugs & Medical Equipment
25
Policies
16
Studies & Reports
13
Community Health
11
Dermatology
9
NTDs & Others
8
Dental & Eye Care
5
Vector Control
5
Countries
5
Helminthiasis
4
Lymphaticfilariasis
4
Community Health
4
Hemorrhagic Fever
4
Statistics
4
HIV & STI
4
Disease Prevention & Control
4
Onchocerciasis
3
Yellow Fever
3
Under-5 nutrition
2
Schistosomiasis
2
Water, Sanitation and Hygiene (WASH)
2
Public Health
2
Pediatrics
2
Policies & Guidelines HIV & TB
2
Women & Child Health
2
Disabilities
2
Other
2
WASH
2
General Guidelines
2
Communicable Diseases
2
Health Systems
2
Nutrition
2
Primary Health Care
2
Communicable Diseases
1
Paediatrics
1
Pharmacy & Technology
1
Child Health
1
Trachoma
1
Taeniasis/ Cysticercosis
1
Cancer
1
Cancer Treatment & Resources
1
Infection Control & Prevention (IPC)
1
Clinical Guidelines
1
Information, Education and Communication (IEC)
1
Capacity Building
1
Leprosy
1
Parasitology
1
Leishmaniasis
1
Human African Trypanosomiasis
1
Malaria
1
Food Security & Nutrition
1
Toolboxes
Country specific documents
26
Clinical Guidelines
25
Essential Medicines & Devices Lists
10
Community Health Workers CHW
8
Onchocerciasis
7
Studies & Reports
6
Prevention & Control
6
Overview, Studies & Reports
6
Treatment Guidelines
5
Essential Medicines
5
Paediatrics
4
Essential Medicines & Medical Devices
4
Strategies & Roadmaps
4
NTDs General
4
Others
3
Clinical Aspects & Diagnostics
3
Information & Education Material (IEC)
3
Capacity Building & Resource platforms
3
Echinocccosis
3
Scabies
3
Vision Loss & Blindness
3
Neurological disorders, Others
3
Treatment & Prevention
2
Yellow Fever Prevention & Control
2
Ebola
2
Topics
2
For Health Worker
2
Global Impact: Socio-economic, health services, TB & HIV
2
Health Care Professionals & Spirituality
2
Mythbusters/Misinformation
2
Tips & Best Practice Examples
2
Rational use of Medicine
2
Capacity Building & Resources
2
Statistics & Facts
2
Studies & Reports
2
Information & Education Material (IEC)
2
General
2
Co-Morbidities (except TB)
2
Africa
1
Agriculture & Veterinary
1
Information & Education Material (IEC)
1
Communication & Training
1
Hygiene
1
Inclusion
1
Training Material
1
Health & Refugee
1
Prevention & Preparedness
1
COVID-19
1
COVID-19
1
Training, others
1
Scientific & Research Studies
1
Hospital Readiness/Essential Health Services
1
Community Health
1
Primary Care
1
Nurses
1
Overview & reports
1
Prices and Patents
1
Information Refugees Ukraine
1
Prevention & Measures
1
General
1
Capacity Building & Resources
1
Capacity Building & Resources
1
Clinical Aspects & Diagnostics
1
Information & Education Material (IEC)
1
Studies & Reports
1
Studies & Reports
1
Studies & Reports
1
Vector control
1
Taeniasis/Cysticercosis
1
General Information & Methodology
1
General
1
Policy
1
Miscellaneous
1
Public Health Administration
1
Clinical Guidelines
1
WASH
1
Volunteers
1
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of ivermectin to treat patients with COVID-19 needing mechanical venti...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi...
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by the public in African Union Member States.
Currently...
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ...
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE...
3 March 2022
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an ...
La presente publicación describe la literatura científica revisada sobre las intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019. El Ministerio de Salud solicitó la revisión de la evidencia disponible para nueve intervenciones terapéuticas frente a COVID-...
his first edition describes the standard operating procedures for health products for NTDs amenable to preventive chemotherapy and the medicines donated to treat them. These include albendazole for lymphatic filariasis and soil-transmitted helminthiases; azithromycin for trachoma and yaws; diethylca...
The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown...
In South and Central America, lymphatic filariasis (LF) is caused by Wuchereria bancrofti, which is transmitted by Culex quinquefasciatus, the only vector species in this region. Of the seven countries considered endemic for LF in the Americas in the last decade, Costa Rica, Suriname and Trinidad a...
The Onchocerciasis Control Programme in West Africa (OCP) undertook regional and large scale frght against onchocerciasis in West Africa in 1974 using a vector control strategy. By 2002 OCP had succeeded in eliminating the disease as a public health, socio-economic and development problem in 10 out ...
Onchocerciasis used to be an important public health problem in Africa, with over 37 million people infected and millions suffering from debilitating skin disease, terrible itching, impaired vision and
blindness. But the epidemiological situation has improved dramatically over the last two decades....
Onchocerciasis – or “river blindness” – is a parasitic disease caused by the filarial worm
Onchocerca volvulus. It is transmitted through the bites of infected blackflies (Simulium spp.) that
breed in fast-flowing rivers and streams, mostly in remote villages located near fertile land wher...
Onchocerciasis causes skin and eye disease, visual impairment and neurological problems. It is mostly found in Africa, but also in Latin America and Yemen. The common name, ‘river blindness,’ gives a good indication where the disease can be found: the vector of the parasite, a small black fly of...
Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamazine and albendazole) or DA (diethylcarbamazine and ...
Following the publication of Guidelines on certification of elimination of human onchocerciasis in 2001 by the World Health Organization (WHO), these are the first evidence-based guidelines developed by NTD Department according to the international standards. They provide a set of recommendations th...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for...
Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030 (“the road map”) sets explicit targets for the elimination of onchocerciasis by 2030, including eliminating the need for mass drug administration (MDA) of ivermectin in at least...
WHO guideline on preventive chemotherapy for public health control of strongyloidiasis
recommended
Human strongyloidiasis is a chronic parasitic disease caused by infection with Strongyloides stercoralis, a soil-transmitted helminth that is estimated to infect 300–600 million people worldwide. This neglected tropical disease (NTD) is endemic globally, predominately in the South-East Asia, Afric...
